Monoclonal Antibody Therapy

Novel COVID-19 monoclonal antibody therapy

Currently two monoclonal antibody therapies have been authorized under a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). The limited supply, and restrictions imposed by the FDA, authorize the use of these treatments to only a small subset of the COVID-19 positive cases. In Utah, the product received from the Federal Government is estimated to treat between 2-5% of the eligible population.

In addition to Eligibility Criteria, there are a number of Inclusion Criteria as defined by the EUA that specify who is eligible for this novel treatment.

COVID-19 Research Studies and Trials

A variety of Utah-based clinical trials and studies are underway, please see for more information on those studies.